Benjamí Oller-Salvia

TL;DR: Although the BBB barrier prevents most drugs from reaching their targets, molecular vectors such as peptide shuttles offer great promise to safely overcome this formidable obstacle as mentioned in this paper and have received growing attention because of their lower cost, reduced immunogenicity, and higher chemical versatility than traditional Trojan horse antibodies and other proteins.

TL;DR: A full protease-resistant peptide with the capacity to act as a BBB shuttle was obtained and thus enabled the transport of a variety of cargos into the central nervous system.

TL;DR: High yielding expression systems that efficiently incorporate a cyclopropene derivative of lysine into antibodies through genetic‐code expansion are described, demonstrating that CypK is a minimal bioorthogonal handle for the rapid production of stable therapeutic protein conjugates.

TL;DR: Among the analogues designed, the monocyclic lactam‐bridged peptidomimetic MiniAp‐4 was the most permeable and can efficiently deliver a cargo across the blood–brain barrier into the brain parenchyma of mice.

TL;DR: It is shown that not only apamin is indeed able to penetrate the blood-brain barrier in a cell-based model but also that an analog reported to be nontoxic passes through this barrier.